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ORIGINAL ARTICLE
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Abstract
Context: Salvianolic acids are the most abundant water-soluble compounds extracted from the
herb Salvia miltiorrhiza L. (Lamiaceae) with antioxidant and protective effects.
Objective: This study evaluates the antidiabetic effect of salvianolic acid B (Sal B) in multiple
low-dose streptozotocin (MLDS)-induced diabetes in rat.
Materials and methods: Rats were divided into control, Sal B40-treated control, diabetic,
Sal B20-, and Sal B40-treated diabetic groups. Sal B was daily administered at doses of 20 or
40mg/kg (i.p.), started on third day post-STZ injection for 3 weeks. Serum glucose and insulin
level and some oxidative stress markers in pancreas were measured in addition to the oral
glucose tolerance test (OGTT), histological assessment, and apoptosis determination.
Results: After 3 weeks, treatment of diabetic rats with Sal B20 and Sal B40 caused a significant
decrease of the serum glucose (p50.05–0.01) and improvement of OGTT. Meanwhile, serum
insulin was significantly higher in Sal B20- and Sal B40-treated diabetics (p50.01) and
treatment of diabetics with Sal B40 significantly lowered malondialdehyde (MDA) (p50.05),
raised glutathione (GSH) (p50.05), and activity of catalase (p50.01) with no significant
change of nitrite. Furthermore, the number of pancreatic islets (p50.05) and their area
(p50.01) was significantly higher and apoptosis reactivity was significantly lower (p50.05) in
the Sal B40-treated diabetic group versus diabetics.
Discussion and conclusion: Three-week treatment of diabetic rats with Sal B exhibited
antidiabetic activity which is partly exerted via attenuation of oxidative stress and apoptosis
and augmentation of antioxidant system.
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Introduction
Diabetes mellitus (DM) comprises a heterogeneous group
of metabolic disorders characterized by defect in glucose
regulation and ensuing hyperglycemia (Maraschin Jde, 2012).
Type 1 DM is a serious condition due to an autoimmune
process and characterized by the infiltration of T-cells,
macrophages, and natural killer cells into and around islets
of Langerhans that is followed by selective destruction of
insulin-secreting beta cells (Bending et al., 2012). In addition
to enhanced oxidative stress burden, antioxidant defense
systems are markedly disturbed in diabetic pancreas, leading
to eventual apoptotic cell death (Cernea & Dobreanu, 2013;
Zhu et al., 2014). The diabetogenic agent streptozotocin
(STZ) is widely used to induce diabetes due to its specific
toxic effect on pancreatic beta cells in rodents like rat
(Nasri et al., 2011). Multiple low-dose streptozotocin (MLDS)
induces diabetes via autoimmunity-mediated destruction of
pancreatic b-cells (Xiang et al., 2010), which resembles its
pathologic process in patients with type 1 DM (Chang et al.,
2013).
Salvianolic acids, especially salvianolic acid B (Sal B),
are the most abundant water-soluble compounds extracted
mainly from the medicinal herb Salvia miltiorrhiza L.
(Lamiaceae), also known as danshen, with potent antioxida-
tive effect due to their polyphenolic structure (Ho & Hong,
2011). Sal B could protect pancreatic beta-cells against
cytotoxicity (Cheng et al., 2013) and prevent high glucose-
induced apoptosis (Sun et al., 2012). Sal B is capable to
protect vascular endothelial cell against oxidative injury
(Yang et al., 2011). Hepatoprotective effect of Sal B
(Gao et al., 2012) and its protective effect in chronic
pancreatitis (Lu et al., 2009) have also been reported. This
study was undertaken to evaluate the antidiabetic effect of Sal
B in multiple low-dose (MLD) model of type 1 diabetes in rat
and to assess some underlying mechanisms.
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Materials and methods
Animals
Male albino Wistar rats (Pasteur’s Institute, Tehran, Iran)
weighing 210–260 g were housed in an air-conditioned
colony room on a light/dark cycle (21–23 C and a humidity
of 30–40%) and supplied with free access to standard pelleted
diet and tap water. The procedures involving animals use and
care were approved by ethics committee of Iran University of
Medical Sciences (Tehran, Iran) and conducted in conformity
with the National Institutes of Health guidelines.
Experimental procedure
The rats (n¼ 60) were randomly allocated and similarly
grouped into five groups, i.e., control, Sal B40-treated control
(40 mg/kg), diabetic, and Sal B20- and Sal B40-treated
diabetics (20 or 40 mg/kg, respectively). For induction of
autoimmune type 1 DM, streptozotocin (STZ) was adminis-
tered daily (i.p.) for 5 consecutive days at a dose of 20 mg/kg
according to a previous study (Hall et al., 2013). STZ
(Sigma-Aldrich, St. Louis, MO) were freshly dissolved in cold
normal saline. Sal B (Sigma-Aldrich, St. Louis, MO) at doses
of 20 (Sal B20) or 40 (Sal B40) mg/kg (p.o. using a gavage
needle) was daily administered, started on third day post-STZ
injection for 3 weeks. The used doses were selected according
to a previous report (Wang et al., 2011) and our earlier pilot
study. Overnight fasting serum glucose concentration was
measured using the glucose oxidation method (Zistshimi,
Tehran) and blood samples taken from the tail vein before the
study (week 0) and at the end of weeks 1, 2, and 3 after STZ
injection. Body weight was also measured weekly. Serum
insulin concentration was determined by an ELISA technique
(EIA Kit, Cayman Chemical, Ann Arbor, MI) according to
the instructions of the manufacturer.
Oral glucose tolerance test (OGTT)
After overnight fasting (n¼ 7–9 for each group), on the day
of animal sacrifice, blood samples were obtained from
snipped tails by tail milking at 0, 30, 60, 90, and 120 min
after administration of glucose (a 20% solution; 2 g/kg b.w.)
using a gavage needle and the blood glucose measurement
was made using a research-grade glucometer.
Oxidative stress assessment
Pancreas tissues from rats (n¼ 4–5 from each group) were
dissected, washed in cold normal saline, blotted dry, weighed,
then made into 5% tissue homogenate in ice-cold normal
saline, centrifuged at 4 C, the obtained supernatant was
aliquotted, then stored at 70 C until being assayed.
Determination of pancreas malondialdehyde content
The malondialdehyde (MDA) concentration was measured as
described by Kiasalari et al. (2013). The results were expressed
as MDA equivalents using tetraethoxypropane as a standard.
Pancreas nitrite assay
Supernatant nitrite content was measured by the Griess
method according to a previous study (Mirshekar et al., 2010).
Assay of catalase activity
Claiborne’s method (1985) was used for this purpose. Briefly,
H2O2 was added to a mixture of potassium phosphate buffer
and supernatant and the rate of H2O2 decomposition was
assessed by measuring the absorbance changes at 240 nm.
Reduced glutathione measurement (GSH)
Glutathione measurement (GSH) was measured as described
before (Ellman, 1959; Sedlak & Lindsay, 1968). Briefly,
the supernatant was centrifuged with trichloroacetic acid.
Then, phosphate buffer and 505-dithiobis-(2-nitrobenzoic
acid) (DTNB) was added. The mixture was vortexed and
the absorbance was read at 412 nm.
Protein assay
The protein content was measured with the Bradford (1976)
method using bovine serum albumin as the standard.
Pancreas histology
Hematoxylin and eosin staining
Pancreas of animals (n¼ 3 from each group) was fixed in
10% buffered formalin for 2–3 d and then embedded in
paraffin. Tissue sections (5mm thick) were deparaffinized
and rehydrated sequentially in xylene, xylene/ethanol, and
ethanol (100, 95, and 70), and then the sections were placed
in distilled water for 10 min. Sections were stained with
hematoxylin and eosin (H&E) using the standard proto-
col, where cytoplasm stained pink, nuclei stained deep
purple, and pancreatic islets appeared pale in color. Finally,
the average number of islets/mm2 and their area were
calculated.
Apoptosis assay
In order to detect DNA fragmentation and apoptotic cell
death, a transferase dUTP nick-end labeling (TUNEL) assay
was performed using the in situ cell death detection kit
(Roche, Penzberg, Germany). In this assay, four rats from
each group was used and euthanized on day 5 after diabetic
induction by STZ. Briefly, the pancreatic sections were
incubated with proteinase K (100 mg/ml), rinsed, incubated in
3% H2O2, permeabilized with 0.5% Triton X-100, rinsed, and
incubated in the TUNEL reaction mixture. The sections were
rinsed and visualized using a converter-POD and subsequent
incubation with DAB (3–30-diamonobenzidine tetrachloride)
and H2O2, coverslipped and evaluated. A dark brown color
indicating DNA breaks developed. TUNEL reactivity density
was assessed in at least 10 islets for each rat and its average
was taken as the final value.
Data and statistical analysis
All values were given as means ± SEM. For morphometric
and densitometric analysis, UTHSCSA image tool software
(version 3, 2002, UTHSCSA, San Antonio, TX) was used.
Statistical analysis of data was carried out using repeated
measure and one-way ANOVA followed by the Tukey post
hoc test. A statistical p value less than 0.05 considered
significant.
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Results
One rat in the diabetic group was excluded from the study due
to its morbid state and final death. Body weight and serum
glucose data (Figure 1) indicated that before induction of
MLD-STZ diabetes, there were no significant differences
among the experimental groups. At the end of week 3, the
weight of the vehicle-treated diabetic rats was found to be
significantly lower versus control rats (p50.05) and SAL
B40-treated diabetics showed no reduction of body weight as
compared with vehicle-treated diabetics. Untreated diabetic
rats also had an elevated serum glucose level over those of
control rats (p50.0005) and treatment of diabetic rats with
Sal B20 or Sal B40 caused a significant decrease in the serum
glucose (p50.05–0.01) at week 3 versus vehicle-treated
diabetics. In addition, Sal B treatment of control rats at none
of the doses did not produce any significant change regarding
serum glucose level relative to the control group.
Oral glucose tolerance test (OGTT)
The OGTT procedure was performed at the end of week 3
after induction of diabetes (Figure 2). The values are percent
change in blood glucose level at time t, relative to initial blood
glucose level at time 0. In control and control + Sal B40
groups, blood glucose almost returned to its initial value at
min 120, while in the diabetic group, it was still higher than
its initial level. However, in both the treated diabetic groups,
blood glucose level finally resettled to the initial level by
120 min. Meanwhile, changes of blood glucose in all diabetic
groups, especially in treated diabetics, were lower than that of
the control groups.
Serum insulin measurement
The effect of Sal B20 and Sal B40 administration on serum
insulin level is shown in Figure 2. In diabetic rats, serum
insulin showed a significant reduction (p50.001) as com-
pared with the control group and treatment of diabetics with
Sal B20 and Sal B40 significantly improved it (p50.01).
However, the insulin level in the latter groups was still
significantly lower as compared with the control group
(p50.05–0.01).
Oxidative stress markers
With respect to pancreatic biochemical markers (Figure 3),
MLD-STZ diabetes resulted in significant elevation of MDA
(p50.01), decreased nitrite (p50.05), and GSH (p50.05),
and reduced activity of the defensive enzyme catalase
(p50.005) versus the control group and treatment of the
diabetic group with Sal B40 significantly lowered MDA
content (p50.05), raised GSH content (p50.05), and activity
of catalase (p50.01) with no significant effect on nitrite.
Meanwhile, there was no significant changes in the Sal B40-
treated control group relative to control animals regarding
these parameters.
Histological evaluation of the pancreas
Histology of pancreas in control rats in H&E staining was
normal in all the specimens. In the diabetic group, a
significant decrease of islet numbers/mm2 (p50.01) and
their mean area (p50.01) (Figure 4), an atrophy and
vacuolation and subtle invasion of connective tissues in
parenchyma of pancreatic islets were observed relative to the
control group. These abnormal histological changes dramat-
ically decreased in the diabetic + Sal B40 group as compared
with diabetic one. In this respect, the number of islets/mm2
significantly increased in diabetic + Sal B20 (p50.05) and
diabetic + Sal B40 (p50.05) groups as compared with
diabetic one. Regarding the islets mean area, it significantly
decreased in the diabetic group as compared with the control
group (p50.01) and it showed significant increase in the
diabetic + Sal B40 group in comparison with the diabetic
group (p50.01).
Apoptosis assay
With respect to islet cell apoptosis (Figure 5), islet cells
undergoing apoptosis were determined by TUNEL assay.
Using a densitometric method, it was found out that reactivity
density was significantly greater in the diabetic group versus
control one (p50.005) and this parameter was significantly
lower in diabetic + Sal B20 (p50.05) and diabetic + Sal B40
(p50.05) groups as compared with diabetic one.
Figure 1. Body weight and serum glucose level at different weeks. Sal B20 and Sal B40 indicate salvianolic acid B at doses of 20 and 40 mg/kg,
respectively (n¼ 10–11 for each group). $p50.05 (versus week 0), *p50.005, **p50.001, ***p50.0005 (versus week 0), #p50.05, ##p50.01
(versus diabetic in the same week).
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Discussion
In this study, Sal B administration at a dose of 40 mg/kg for 3
weeks to MLD-STZ diabetic rats exerted a hypoglycemic
effect and prevented body weight reduction, improved OGTT,
and increased serum insulin level, attenuated oxidative stress,
and augmented antioxidant defense system, and prevented
loss and degeneration of pancreatic islets due to its anti-
apoptotic effect.
In our research, we decided to start Sal B administration at
early stages of diabetes process, i.e., several days post-STZ
injection (on third day), not to have a mere protective or
restorative intervention. In this respect, some previous works
have administered their beneficial agents before the first STZ
Figure 3. Pancreas tissue oxidative stress markers. Sal B20 and Sal B40 indicate salvianolic acid B at doses of 20 and 40 mg/kg, respectively (n¼ 4–5
for each group). *p50.05, **p50.01, ***p50.005 (versus control), #p50.05, ##p50.01 (versus diabetic).
Figure 2. Changes of blood glucose as percentage of initial value (min 0) at different time points in OGTT and serum insulin level. Sal B20 and Sal
B40 indicate salvianolic acid B at doses of 20 and 40 mg/kg, respectively (n¼ 7–9 for each group). *p50.05, **p50.01, ***p50.001 (versus control),
#p50.01 (versus diabetic).
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Figure 4. The number of pancreatic islets/mm2 and their mean area (top panel) and photomicrographs of pancreatic sections stained with H&E
(bottom panel) after 3 weeks of Sal B administration. Sal B20 and Sal B40 indicate salvianolic acid B at doses of 20 and 40 mg/kg, respectively (n¼ 3
for each group). *p50.05, **p50.01 (versus control), #p50.05, ##p50.01 (versus diabetic).
Figure 5. Immunoreactivity density for TUNEL assay of pancreatic islets and their photomicrographs on day 5 after diabetic induction by STZ. Sal
B20 and Sal B40 indicate salvianolic acid B at doses of 20 and 40 mg/kg, respectively (n¼ 4 for each group). Each arrow shows a pancreatic islet.
*p50.05, **p50.005 (versus control), #p50.05 (versus diabetic).
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injection in the MLD-STZ model (Amirshahrokhi & Ghazi-
Khansari, 2012) that is a protective strategy and some works
have administered their agents after the last STZ injection in
this model (Jiang et al., 2014) that is more resembled to a
restorative protocol. Even, some researchers have begun first
administration of their protective agent at day 1 post-STZ
injection (Fukudome et al., 2008). In addition, since mono-
nuclear infiltration into pancreatic islets is an initial event
inducing insulitis in the development of type 1 diabetes in the
MLD-STZ model and occurs within several days post-STZ
injection (Takamura et al., 1999), therefore, it is better to
begin the treatment at the first days of diabetes induction.
Although glucose-lowering effect of Sal B was not
observed for the control group in this study, but its
administration for 3 weeks exerted a marked hypoglycemic
effect in diabetic rats, indicating hypoglycemic mechanism of
Sal B to be different in diabetic and non-diabetics. A previous
study has shown that Sal B could protect and even restore
function of pancreatic beta cells (Cheng et al., 2013), in this
way possibly exerting its anti-hyperglycemic and antidiabetic
effect. In addition, it has been shown that Sal B has protective
effect in mammalian cells against toxicity induced by high
glucose condition through inhibition of apoptotic pathway
(Sun et al., 2012) that was also observed in our study.
Until now, there has not been any report on insulinomimetic
and/or insulin releasing ability of SAL B, thus it is more
possible that such compounds act via their anti-oxidant and/or
anti-inflammatory effect, which itself needs further investi-
gation. Histological analysis of the pancreas using H&E
and TUNEL staining showed the degeneration of islets, as
evidenced by their lower area and being less scattered. In
support of this idea, part of deleterious effect of multiple low-
dose STZ is exerted through activation of an apoptotic
pathway (Mensah-Brown et al., 2002) and it has been reported
that Sal B exhibits anti-apoptotic effect via reducing the
expression of tumor necrosis factor alpha receptor type 1,
balancing the expression of Bcl-2 family members, reducing
the release of cytochrome C from the mitochondria into the
cytosol, and inhibiting activated caspase-3 (Yan et al., 2010).
Thus, these mechanism may be of significance in such studies
and warrant more researches in future.
Sal B treatment could also attenuate the inflammation
induced by some toxic agents (Gao et al., 2012), therefore,
part of its beneficial effect in our study could be attributed to
its anti-inflammatory property (Chen et al., 2011). In this
respect, Sal B could suppress the expression of pro-inflam-
matory cytokines TNF-a and IL-1b, whereas enhance the
expression of anti-inflammatory cytokines IL-10 and TGF-b1
(Chen et al., 2011). The same mechanism may have occurred
in our study to produce the protective role of Sal B in the
MLD-STZ model of diabetes and suggest that its protective
effect might be associated with its anti-inflammatory activity.
However, determination of exact mode of action of Sal B in
this model is strongly recommended.
Reactive oxygen species (ROS) and NO also have crucial
roles in pathogenesis of diabetes complications
(Baluchnejadmojarad et al., 2013). Possible sources of
oxidative stress in diabetes include an increased production
of ROS, especially from enhanced glycation and lipoxidation
processes (Fiorentino et al., 2013). Substantial evidence
suggest that Sal B could elicit anti-oxidant properties by
attenuating the lipid peroxidation caused by various forms
of free radicals and to boost antioxidant defensive system
(Yang et al., 2011), in this way may have exerted its
antidiabetic effect in our study. This fact was verified by a
lower MDA content, raised GSH, and an increased activity of
catalase in pancreatic tissue of treated diabetics in this study.
Finally, one of the limitations of our study was that we did
not have a positive control group and, for this reason, we
could not directly compare the magnitude of the effect of
Sal B in this study with other available drugs.
The data obtained from the present study indicate
antidiabetic effect of Sal B in the MLD-STZ model of
diabetes. We provide evidence for the first time that Sal B
may exert antidiabetic effect by protecting pancreatic beta cell
against chemical insult and may also improve insulin
secretory function of beta cells. Since the loss of functional
beta cell mass is the key for deterioration of glycemic control
in diabetic patients, more researches are warranted to further
characterize and unravel the molecular mechanisms under-
lying the antidiabetic effect of Sal B.
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